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Abstract
Background: The Dachshund homolog 2 (DACH2) gene has been implicated in development of the female genital
tract in mouse models and premature ovarian failure syndrome, but to date, its expression in human normal and
cancerous tissue remains unexplored. Using the Human Protein Atlas as a tool for cancer biomarker discovery,
DACH2 protein was found to be differentially expressed in epithelial ovarian cancer (EOC). Here, the expression and
prognostic significance of DACH2 was further evaluated in ovarian cancer cell lines and human EOC samples.
Methods: Immunohistochemical expression of DACH2 was examined in tissue microarrays with 143 incident EOC
cases from two prospective, population-based cohorts, including a subset of benign-appearing fallopian tubes (n =
32). A nuclear score (NS), i.e. multiplier of staining fraction and intensity, was calculated. For survival analyses, cases
were dichotomized into low (NS < = 3) and high (NS > 3) using classification and regression tree analysis. Kaplan
Meier analysis and Cox proportional hazards modelling were used to assess the impact of DACH2 expression on
survival. DACH2 expression was analysed in the cisplatin sensitive ovarian cancer cell line A2780 and its cisplatin
resistant derivative A2780-Cp70. The specificity of the DACH2 antibody was tested using siRNA-mediated silencing
of DACH2 in A2780-Cp70 cells.
Results: DACH2 expression was considerably higher in the cisplatin resistant A2780-Cp70 cells compared to the
cisplatin-sensitive A2780 cells. While present in all sampled fallopian tubes, DACH2 expression ranged from negative to
strong in EOC. In EOC, DACH2 expression correlated with several proteins involved in DNA integrity and repair, and
proliferation. DACH2 expression was significantly higher in carcinoma of the serous subtype compared to non-serous
carcinoma. In the full cohort, high DACH2 expression was significantly associated with poor prognosis in univariable
analysis, and in carcinoma of the serous subtype, DACH2 remained an independent factor of poor prognosis.
Conclusions: This study provides a first demonstration of DACH2 protein being expressed in human fallopian
tubes and EOC, with the highest expression in serous carcinoma where DACH2 was found to be an independent
biomarker of poor prognosis. Future research should expand on the role of DACH2 in ovarian carcinogenesis and
chemotherapy resistance.
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Background
Epithelial ovarian cancer (EOC) is the fifth most common
cause of cancer-related death in women and the leading
cause of death from gynaecological malignancy [1]. Etiolo-
gical factors involved in ovarian carcinogenesis remain
poorly defined, and effective treatment protocols are lim-
ited. The poor ratio of survival to incidence is related to
the high percentage of cases diagnosed at an advanced
stage, and the symptoms of EOC are often vague and
overlap with other more common gastrointestinal and
gynaecological diseases. Despite aggressive surgery and
chemotherapy, most patients relapse within 3 to 5 years,
and the median time to relapse is 15 months after diagno-
sis [2]. Thus, there is an urgent need for the identification
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for development of personalized therapeutic regimens for
ovarian cancer patients.
Using the Human Protein Atlas http://www.proteina-
tlas.org as a tool for antibody based biomarker discovery
[3,4], the Dachshund 2 (DACH2) protein was identified
as being differentially expressed among EOC samples,
ranging from negative to strong nuclear staining. Based
on this observation, we hypothesized that DACH2
might be involved in ovarian carcinogenesis and, hence,
a putative prognostic and treatment predictive biomar-
ker in EOC.
The dachshund (DACH) gene was first described in
Drosophila, where it encodes a nuclear protein involved
in development of the eyes, limbs and genital disc [5,6].
W h i l eD r o s o p h i l ah a sas i n g l edachshund gene, two
DACH genes, DACH1 and DACH2, have been found in
mice, humans and chicken [7-10] In mice, the DACH1
and DACH2 genes show functional redundancy during
development of the female genital tract, whereby defects
are associated with Müllerian but not Wolffian duct
development [11]. In humans, the DACH2 gene has been
implicated in premature ovarian failure (POF) syndrome
[12,13], indicating that alterations of the human DACH2
protein may constitute a risk-factor for POF by altering
the correct process of ovarian follicle differentiation [13].
While the role of DACH2 in human tumourigenesis
remains unexplored, alterations of DACH1 expression
has been described in several cancer forms, e.g. breast
[14], prostate [15], endometrial [16], gastric [17] and
ovarian cancer [18]. The prognostic value of DACH1
seems to be cancer-type dependent in that reduced
DACH1 levels have been associated with poor prognosis
in breast, gastric, and endometrial cancer [16,17,19] and
with tumour progression in prostate cancer [15], whilst
in EOC, DACH1 has been shown to be up-regulated in
advance-stage ovarian cancer and promote resistance to
TGF-b signaling [18].
The aim of this study was to investigate the prognostic
role of DACH2 protein expression in ovarian cancer, by
immunohistochemical analysis of 154 EOC samples
from two prospective, population-based cohorts.
DACH2 levels were also assessed in a cisplatin sensitive
and resistant ovarian cancer cell line, respectively.
Methods
Patients
The study cohort is a merge of all incident cases of
epithelial ovarian cancers in the population-based pro-
spective cohort studies Malmö Diet and Cancer Study
(n = 101)[20] and Malmö Preventive Medicine Cohort
(n = 108)[21] until Dec 31st 2007. Thirty-five patients
participated in both studies, and archival tumour tissue
could be retrieved from 154 of the total number of 174
cases. Cases were identified from the Swedish Cancer
Registry up until 31 Dec 2006, and from The Southern
Swedish Regional Tumour Registry for the period of 1
Jan - 31 Dec 2007. All tumours were re-evaluated
regarding histological subtype and histological grade by
a board certified pathologist (KJ). Information regarding
clinical stage was obtained from the medical charts, fol-
lowing the standardized FIGO classification of tumour
staging. Information on residual tumour after surgery
was not available. Standard adjuvant therapy was plati-
num-based chemotherapy, from the 1990s given in com-
bination with paclitaxel.
Histopathological, clinical and treatment data were
obtained from the clinical- and/or pathology records.
Information on vital status and cause of death was
obtained from the Swedish Cause of Death Registry up
until 31 Dec 2008. Follow-up started at date of diagnosis
and ended at death, emigration or 31 Dec 2008, which-
ever came first. After a median follow-up of 2.65 years
(range 0-21), 105 patients (68.2%) were dead and 49
(31.8%) alive. Patient-and tumour characteristics of the
cohort have been described in detail previously [22-24].
Ethical permissions for the MDCS (Ref. 51/90), and the
present study (Ref. 530/2008), were obtained from the
Ethics Committee at Lund University.
Tissue microarray construction and
immunohistochemistry
Areas representative of cancer were marked on full-face
haematoxylin and eosin stained sections and TMAs con-
structed as previously described [25]. In brief, 2-4 1.0
mm cores were taken from each tumour and mounted in
a new recipient block using a semi-automated arraying
device (TMArrayer; Pathology Devices, Inc, Westminster,
MD, USA).
For immunohistochemical analysis of DACH2, 4 μm
TMA-sections were automatically pretreated using the
PT-link system (DAKO, Glostrup, Denmark) and then
stained in a Autostainer Plus (DAKO) with a polyclonal
anti-DACH2 antibody (HPA0000258, Atlas Antibodies
AB, Stockholm, Sweden) diluted 1:50. Immunohisto-
chemistry for RBM3, Chek1, Chek2, MCM3, estrogen
receptor a (ER), progesterone receptor (PR), and andro-
gen receptor (AR) was performed as previously
described [22-24]. Ki67 was analysed using a monoclo-
nal antibody (MIB-1, DAKO, diluted 1:200)
Analysis of immunohistochemical staining
DACH2 was primarily expressed in the nucleus and for
assessment of DACH2 expression, both the fraction of
positive cells and staining intensity were taken into
account. Nuclear fraction was categorized into four
groups, namely 0 (0-1%), 1 (2-25%), 2 (26-75) and 3
(> 75%) and nuclear staining intensity denoted as 0-3,
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3 = strong intensity. A combined nuclear score (NS) was
then constructed as a multipler of DACH2 nuclear frac-
tion and intensity, thus ranging from 0 to 9. Ki67 was
annotated as the fraction of positive staining cells and
denoted as 0 (0-1%), 1(2-25%), 2(26-50%) and 3(> 50%).
Cell lines and reagents
The human ovarian cancer cell line A2780 and the cis-
platin-resistant variant A2780-Cp70 were maintained in
RPMI-1640 supplemented with glutamine, 10% fetal
bovine serum and 1% pencillin/streptomycin in a humi-
dified incubator of 5% CO2 at 37°C.
Real-time quantitative PCR and Western Blotting
Total RNA isolation (RNeasy, QIAgen, Hilden, Germany),
cDNA synthesis (Reverse Transcriptase kit, Life Technolo-
gies, Carlsbad, Ca, USA) and quantitative real-time PCR
(qRT-PCR) analysis of DACH2 expression with TaqMan
Gene Expression Assay (Hs 00364968, Life Technologies)
was performed according to the manufacturers instruc-
tions. Quantification of expression levels were calculated
by using the comparative Ct method, normalization
according to the house keeping gene 18S (s03928990 g1
RN 18S1; Life Technologies).
For immunoblotting, cells were lysed in ice-cold RIPA
buffer (Cayman Chemical Company, Ann Arbor, MI,
USA) and supplemented with protease inhibitor cocktail
Complete Mini (Roche, Basel, Switzerland). Thirty μgo f
protein were separated on 4-12% Nu-PAGE Bis-Tris gels
and transferred onto iBlot Gel Transfer Stacks Nitrocel-
lulose (Life technologies). DACH2 was detected by the
polyclonal DACH2 antibody (HPA 0000258, Atlas Anti-
bodies AB) diluted 1:250 in blocking solution, (Wester-
nBreeze Chemiluminescent Immunodetection System
(Life technologies) followed by a secondary antibody
solution, Alk-Phos Conjugated, Anti-Rabbit (Wester-
nBreeze Chemiluminescent Immunodetection System,
Life technologies) and visualized using WesternBreeze
Chemiluminescent Immunodetection System (Life tech-
nologies). Membranes were stripped and re-probed with
an anti-b-actin antibody (Santa Cruz, Biotechnology,
Santa Cruz, CA, USA) at a dilution of 1:1000, to provide
a loading control.
Cell pellet arrays
Cell lines were fixed in 4% formalin and processed in
gradient alcohols. Cell pellets were cleared in xylene and
washed multiple times in molten paraffin. Once pro-
cessed, cell lines were arrayed in duplicate 1.0 mm cores
using a manual tissue arrayer (Beecher Inc, WI, USA)
and IHC was performed on 4 μm sections using the
DACH2 antibody diluted 1:50.
siRNA mediated knockdown of DACH2 gene expression
Transfection with siRNA against DACH2 (Life Technol-
ogies) or control siRNA (Life Technologies) was per-
formed with Lipofectamine 2000 (Life Technologies)
with a final concentration of 50 nM siRNA. Two inde-
pendent RNA oligonucleotides (s229511 and s229512,
Life Technologies) targeting DACH2 were used.
Statistical analysis
Spearman’s Rho test was used for comparison of DACH2
expression and clinicopathological and tumour biological
characteristics. Classification regression tree (CRT) analy-
sis was used to decide optimal cutoff for survival analysis.
Kaplan-Meier analysis and log rank test were used to illus-
trate differences in ovarian cancer specific survival (OCSS)
and overall survival (OS) according to DACH2 expression.
Cox regression proportional hazards models were used for
estimation of hazard ratios (HRs) for death from ovarian
cancer or overall causes according to DACH2 expression
in both uni- and multivariable analysis, adjusted for stage
and differentiation grade. Experimental data are expressed
as mean ± SD of three independent experiments. Statisti-
cal significance of differences between means was deter-
mined by Student’s t test. All calculations were performed
using IBM SPSS Statistics Version 20 (SPSS Inc, Chicago,
IL). All statistical tests were two-sided and a p value < 0.05
was considered statistically significant.
Results
Antibody validation and comparison of DACH2 levels in
cisplatin-sensitive vs cisplatin-resistant ovarian cancer cells
DACH2 protein expression, assessed by both IHC and
Western blotting, was substantially higher in the cispla-
tin-resistant derivative A2780-Cp70 cells compared to
the parental A2780 cells, in which the DACH2 protein
was barely detectable (Figure 1A and 1B). Real-time
quantitative PCR (qRT-PCR) confirmed a similar differ-
ence whereby there was a 3.7-fold higher level of DACH2
mRNA in the A2780-Cp70 compared to the A2780 cell
line (Figure 1C). Cisplatin resistance in the A2780-Cp70
cells relative to the A2780 cells has been confirmed pre-
viously [23]. The specificity of the DACH2 antibody was
confirmed by siRNA-mediated knockdown of DACH2 in
A2780/Cp70 cells. IHC performed on formalin fixed, par-
affin embedded siRNA transfected A2780/Cp70 cells
revealed a marked decrease in immunoreactivity in the
DACH2 knockdown cells compared to controls as visua-
lized by IHC on cell pellets (Figure 1D).
Immunohistochemical expression of DACH2 in fallopian
tubes and EOC
Following antibody optimisation and staining, DACH2
expression could be evaluated in 32/38 (84.2%) samples
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There was no obvious heterogeneity in DACH2 expression
between duplicate TMA cores. Images representing differ-
ent patterns of expression in tubal epithelium and EOC
are shown in Figure 2 A-H, whereby A-B represent tubal
epithelium, C-E tumours with a NS < = 3 and F-H
tumours with a NS > 3. As regards the staining distribu-
tion, expression of DACH2 protein was evident in all fallo-
pian tubes with nuclear scores ranging from 3-9 (Figure
3A). A wider range of DACH2 expression was observed in
EOC, where 8 (5.6%) cases were denoted as DACH2 nega-
tive and 33 (23.1%) cases had a NS < 3, e.g. lower than in
the tubal epithelium (Figure 3B). There was however no
statistically significant difference in DACH2 expression in
tubal epithelium and EOC in cases from which paired
samples had been analysed (n = 30), of whom 2 had
DACH2 negative tumours, 5 had tumours with a NS < 3,
and the remaining cases (n = 25) had a NS > = 3 in the
invasive component (data not shown). There was no sig-
nificant difference in DACH2 expression between cancer
located to the ovaries and metastatic deposits (data not
shown). DACH2 staining was significantly higher in carci-
nomas of the serous subtype compared to nonserous car-
cinomas (R = 0.244, p = 0.003) (Figure 3C). Comparison
of different histological subtypes within non-serous
carcinomas, i.e. mucinous, endometroid and clear cell car-
cinomas revealed no significant difference in the distribu-
tion of DACH2 staining (data not shown). The
distribution of DACH2 in tubal epithelium was similar in
serous and non-serous carcinomas (data not shown).
Association between DACH2 expression,
clinicopathological characteristics and markers of
proliferation and DNA integrity
Next, we examined the relationship between DACH2
expression (NS) and established clinicopathological and
investigative parameters (Table 1). In the full cohort,
DACH2 expression showed a positive correlation to
Ki67, Chk1, Chk2 and MCM3 expression. There was no
significant correlation between DACH2 expression and
established clinicopathological factors, i.e. clinical stage
a n dg r a d e ,n o rt oR B M 3 ,A R ,E Ro rP Re x p r e s s i o n .I n
the serous subtype, DACH2 was not significantly asso-
ciated with any other clinicopathological or tumour bio-
logical parameters (Table 1).
Association between DACH2 expression and survival from
EOC
CRT analysis suggested an optimal cutoff point at NS >
3 to determine the impact of DACH2 expression on
Figure 1 Expression of DACH2 in the cisplatin-sensitive A2780 ovarian cancer cell line compared to the cisplatin-resistant cell line A2780-
Cp70 and validation of the specificity of the DACH2 antibody in A2780 ovarian cancer cells. Substantially higher DACH2 protein expression
was seen in the cisplatin-resistant A2780-Cp70 cell line compared to its parental cisplatin-sensitive A2780 cell line by A) immunocytochemical staining
and (B) immunoblotting, showing a major band at 62 kDa corresponding to the expected molecular weight of the DACH2 protein. (C) Relative mRNA
expression was also higher in the A2780-Cp70 cells compared to A2780 cells as shown by qRT-PCR analysis. Data shown are mean ± SD of a
representative experiment of two independent experiments performed in triplicate. (D) DACH2 protein expression was significantly decreased after
transfection with siRNA against DACH2 in A2780-Cp70 cells as shown by immunocytochemistry 72 hrs post-transfection.
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cohort (n = 143) demonstrated a significantly reduced
OCSS (p = 0.046) and OS (p = 0.021) for tumours
expressing high levels of DACH2 (Figure 4A, B). These
associations were accentuated in the subgroup of serous
carcinoma (n = 84) for both OCSS (p = 0.008) and OS
(p = 0.004) (Figure 4C, D). The associations between
DACH2 expression and survival were confirmed in uni-
variable Cox regression analysis (Table 2). In multivari-
able analysis, DACH2 remained an independent
Figure 2 Immunohistochemical images of DACH2 staining in fallopian tubes and ovarian cancer. Images (20× magnification) representing
immunohistochemical expression of DACH2 in (A, B) fallopian tubes, and EOC ranging from (C) negative, (D) weak intensity in few cells, (E) weak
intensity in majority of cells, (F) moderate to strong intensity in majority of cells, (G) strong intensity in majority of cells and (H) strong intensity
in all tumour cells.
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and ovarian cancer. Bar charts visualizing the staining distribution
of DACH2 in (A) fallopian tubes and (B) ovarian cancer, and (C) in
serous vs non-serous carcinoma. NS = nuclear score, e.g. a multiplier
of fraction (0-3) and intensity (0-3) of staining.
Table 1 Associations between DACH2 expression and
clinicopathological parameters in all patients and
patients with serous carcinoma.
All Serous carcinoma
Factor DACH2 DACH2
Age
R 0.044 0.078
p 0.603 0.483
n 143 84
Differentiation grade
R -0,031 -0.189
p 0.716 0.086
n 143 84
Clinical stage
R 0.025 0.078
p 0.779 0.494
n 131 80
Ki67
R 0.208 0.086
p 0.013* 0.435
n 141 84
AR
R 0.028 -0.045
p 0.738 0.683
n 143 84
ER
R 0.122 -0.067
p 0.151 0.554
n 139 81
PR
R 0.130 0.085
p 0.126 0.437
n 141 85
RBM3
R -0,072 -0.167
p 0.393 0.129
n 141 84
Chek1
R 0.194 0.139
p 0.024* 0.225
n 134 78
Chek2
R 0.182 0.155
p 0.032* 0.164
n 139 78
MCM3
R 0.252 0.104
p 0.003** 0.360
n 134 79
R = Spearman’s correlation coefficient, p = p-value, n = number of cases
available for analysis. ER = estrogen receptor, PR = progesterone receptor, AR
= Androgen receptor. *significance at 5% level, ** significance at 1% level.
The analysis are based on multipliers of staining intensity and fraction
(nuclear score) for DACH2, RBM3, Chek1, Chek2 and MCM3 and categories of
nuclear fraction for Ki67, AR, ER, and PR.
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both OCSS (HR = 2.01, 95% CI 1.05-3.85, p = 0.035)
and OS (HR = 2.13, 95% CI 1.12-4.08, p = 0.022), but
not in the full cohort (Table 2). DACH2 was not prog-
nostic in separate analysis of other histological sub-
groups (data not shown). Ki67 expression was not
prognostic, neither in the full cohort nor in the sub-
group of serous carcinoma (data not shown).
Discussion
The results from this study provide a first demonstra-
tion of DACH2 being abundantly expressed at the pro-
tein level in human fallopian tubes and EOC. Moreover,
DACH2 expression was found to be significantly higher
in EOC of the serous subtype compared to non-serous
carcinoma, and an independent predictor of poor survi-
val in the former.
In the full cohort of EOC, there was a positive correla-
tion between expression of DACH2 and crucial check-
point proteins and regulators of cellular DNA damage
response Chek1 and Chek2 [26], as well as MCM3, a key
component of the DNA replication licensing system [27].
High expression of Chek1, Chek2 and MCM3 has pre-
viously been demonstrated to be associated with a poor
prognosis in the here studied cohort of tumours, although
not independent of other established clinicopathological
parameters [24]. Moreover, the positive association
between DACH2 and Ki67 further supports a role for
DACH2 in conferring a more malignant phenotype in
EOC.
The association of DACH2 expression with proteins
involved in maintenance of DNA integrity might suggest
a role for DACH2 in chemotherapy resistance, a notion
further supported by the finding of substantially higher
Figure 4 Kaplan-Meier estimates of ovarian cancer specific and overall survival in all patients according to DACH2 expression. Kaplan
Meier analysis of ovarian cancer specific and overall survival in strata of low and high DACH2 expression in (A, C) all patients, and (B, D) serous
carcinoma. The categories of staining were determined according to the nuclear score (NS), e.g. a multiplier of fraction and intensity, whereby
low expression = NS < = 3 and high expression = NS > 3.
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A2780-Cp70 compared to cisplatin sensitive A2780 ovar-
ian cancer cells. It would therefore be of interest to
address the molecular basis for how DACH2 might mod-
ulate the effects of both platinum and taxane-based che-
motherapy in future mechanistic studies. However, the
association between DACH2 expression and other inves-
tigative markers, e.g. Chek1, Chek2, MCM3 and Ki67,
was only evident in the full cohort and not in the sub-
group of serous carcinoma, where DACH2 expression
was significantly higher than in non-serous carcinomas,
and an independent factor of poor prognosis. These find-
ings, together with the various important developmental
functions demonstrated for DACH proteins, not least
related to the female genital tract [11-13], indicate that
DACH2 might play a more important role in EOC devel-
opment than in chemotherapy resistance. As DACH2
was found to be expressed in the epithelium of all conco-
mitantly sampled benign-appearing fallopian tubes and a
significant proportion of serous carcinomas have been
suggested to arise within the fimbrial tubal epithelium
[28-30], these observations could indicate differential
roles of DACH2 in the progression of serous and non-
serous carcinomas, respectively.
While DACH1 has been demonstrated to co-localize
with ER in breast cancer and AR in normal prostate and
exert repressive effects on both ER and AR mediated
signaling [14,15], no correlation was found between
expression of DACH2 and AR, ER or PR in the here
examined EOC cohort. However, these findings do not
exclude a role for DACH2 as a mediator of endocrine
signaling in EOC.
Apart from providing a first description of the expres-
sion and prognostic significance of DACH2 in EOC, this
is also, to our knowledge, the first report of DACH2
expression in any human cancer form. This illustrates
the utility of the Human Protein Atlas as a tool for anti-
body-based biomarker discovery [3], not least in light of
the lack of well-validated antibodies in translational
research, but also since it facilitates the selection of
hypotheses relevant to human disease. The specificity of
the polyclonal antibody generated against DACH2
within the HPA project was here further validated by a
marked reduction of DACH2 expression in formalin-
fixed, paraffin-embedded siDACH2 treated EOC cells
compared to controls, confirming its suitability for use
in immunohistochemical biomarker studies. Although
being a semi-quantitative method, immunohistochemis-
try has several advantages compared to other assays, not
least in the clinical setting, as it is simple to perform,
fast and comparatively cheap. More importantly, it
allows for marker analysis in different subcellular loca-
tions, which might be of crucial importance for prog-
nostication and treatment stratification of patients.
Interestingly, loss of DACH1 expression has been
associated with poor prognosis in all hitherto investi-
gated cancer forms with the exception of ovarian cancer,
where gene expression profiling analysis identified
DACH1 to be up-regulated in advance-stage ovarian
cancer and to inhibit TGF-b signaling in ovarian cancer
cells [18]. Whether DACH2 is prognostic in other can-
cer forms, and to what extent this might be cancer-type
specific, will be of interest to determine in future
studies.
Table 2 Relative risks of death from ovarian cancer and overall death according to DACH2 expression in all patients
and patients with serous carcinoma.
Ovarian cancer specific survival Overall survival
HR(95%CI) p-value n(events) HR(95%CI) p-value n(events)
All Univariable Univariable
DACH2 low 1,00 0.048 60 1,00 0.022 60
DACH2 high 1.54(1.00-2.35) 83 1.63(1.07-2.47) 83
Multivariable Multivariable
DACH2 low 1,00 0.182 55 1,00 0.088 55
DACH2 high 1.36(0.87-2.12) 76 1.57(0.95-2.28) 76
Serous carcinoma Univariable Univariable
DACH2 low 1,00 0.010 28 1,00 0.005 28
DACH2 high 2.21(1.21-4.04) 56 2.34(1.23-4.26) 56
Multivariable Multivariable
DACH2 low 1,00 0.035 25 1,00 0.022 25
DACH2 high 2.01(1.05-3.85) 51 2.13(1.12-4.08) 51
Cox uni- and multivariable analysis of relative risks of death from ovarian cancer and overall death according to DACH2 expression in all patients and patients
with serous carcinoma. HR = Hazard ratio. The categories of staining were determined according to the nuclear score (NS), e.g. a multiplier of fraction and
intensity, whereby low expression = NS < = 3 and high expression = NS > 3. Multivariate analysis included adjustment for differentiation grade (low-intermediate
vs high) and clinical stage (1-2 vs 3 and 4).
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Using an antibody-based biomarker discovery approach,
DACH2 has been identified as a novel biomarker of
poor prognosis in EOC. Future studies are warranted to
confirm these findings in additional patient cohorts and
to further elucidate the role of DACH2 in ovarian carci-
nogenesis, progression and chemotherapy response.
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